13 November 2017 - The Scottish Medicines Consortium has today published advice accepting three new medicines for use by NHSScotland.

Olaratumab (Lartruvo) was accepted for the treatment of advanced soft tissue sarcoma, a rare type of cancer that affects the soft, supportive tissues of the body such as muscles, blood vessels and fat tissue. 

Pegvisomant (Somavert) for the treatment of acromegaly was also accepted through the PACE process. 

Also accepted was glecaprevir / pibrentasivir (Maviret) for the treatment of chronic hepatitis C, a blood-borne virus that predominantly infects the cells of the liver, resulting in inflammation and significant damage and potentially liver failure or cancer. Glecaprevir / pibrentasivir is given as a short-term course of oral treatment which is associated with a high response rate and offers the prospect of a cure across all types of hepatitis C.

Read SMC press release